Mohammad Hazaymeh, Vesna Malinova, Lidia Stork, Imke Metz, Christine Stadelmann, Torge Huckhagel, Leif Hendrik Dröge, Rami El Shafie, Dorothee Mielke, Veit Rohde, Tammam Abboud
{"title":"组织病理学证实的放射性坏死:原发性脑肿瘤患者的危险因素和临床结果。","authors":"Mohammad Hazaymeh, Vesna Malinova, Lidia Stork, Imke Metz, Christine Stadelmann, Torge Huckhagel, Leif Hendrik Dröge, Rami El Shafie, Dorothee Mielke, Veit Rohde, Tammam Abboud","doi":"10.1093/nop/npaf021","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Radiation necrosis is a recognized complication following radiotherapy for primary brain tumors, presenting diagnostic and therapeutic challenges, and potentially masquerading as tumor recurrence. This study aims to delineate the clinical trajectory, management strategies, and outcomes of histologically confirmed radiation necrosis in patients treated for primary brain tumors.</p><p><strong>Methods: </strong>We conducted a retrospective review of patients who underwent surgical intervention for suspected tumor recurrence at our institution between 2010 and 2022, following adjuvant radiotherapy. Cases with histopathologically confirmed radiation necrosis were identified and analyzed for onset, clinical symptoms, radiological features, correlation with radio- and chemotherapy, management approaches, and disease progression.</p><p><strong>Results: </strong>Out of 276 patients operated for suspected recurrent brain tumors, 14 (5%) were histopathologically diagnosed with radiation necrosis. The latency period from radiotherapy to diagnosis ranged from 3 to 40 months. Notably, patients with oligodendrogliomas exhibited a significantly higher incidence of radiation necrosis (26%), underscoring a substantial risk association (<i>P</i> < 0.001). Conversely, the rates of radiation necrosis in patients with glioblastoma and astrocytoma (WHO grade II and III) were lower, at 2% and 0%, respectively, suggesting a lower risk association (<i>P</i> < 0.001 and <i>P</i> = 0.036, respectively). The majority (79%) of these patients were asymptomatic and exhibited a favorable clinical course, with most cases showing no progression of necrosis. During the follow-up period, tumor recurrence was verified in 2 patients.</p><p><strong>Conclusion: </strong>Radiation necrosis post-radiotherapy for primary brain tumors occurs infrequently but predominantly in patients with oligodendrogliomas, often following a benign course. The study underscores the importance of close monitoring for this condition, given the potential for sampling errors and the critical need for histopathological confirmation to guide appropriate management.</p>","PeriodicalId":19234,"journal":{"name":"Neuro-oncology practice","volume":"12 4","pages":"670-677"},"PeriodicalIF":2.5000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349754/pdf/","citationCount":"0","resultStr":"{\"title\":\"Histopathologically confirmed radiation necrosis: Risk factors and clinical outcomes in patients with primary brain tumors.\",\"authors\":\"Mohammad Hazaymeh, Vesna Malinova, Lidia Stork, Imke Metz, Christine Stadelmann, Torge Huckhagel, Leif Hendrik Dröge, Rami El Shafie, Dorothee Mielke, Veit Rohde, Tammam Abboud\",\"doi\":\"10.1093/nop/npaf021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Radiation necrosis is a recognized complication following radiotherapy for primary brain tumors, presenting diagnostic and therapeutic challenges, and potentially masquerading as tumor recurrence. This study aims to delineate the clinical trajectory, management strategies, and outcomes of histologically confirmed radiation necrosis in patients treated for primary brain tumors.</p><p><strong>Methods: </strong>We conducted a retrospective review of patients who underwent surgical intervention for suspected tumor recurrence at our institution between 2010 and 2022, following adjuvant radiotherapy. Cases with histopathologically confirmed radiation necrosis were identified and analyzed for onset, clinical symptoms, radiological features, correlation with radio- and chemotherapy, management approaches, and disease progression.</p><p><strong>Results: </strong>Out of 276 patients operated for suspected recurrent brain tumors, 14 (5%) were histopathologically diagnosed with radiation necrosis. The latency period from radiotherapy to diagnosis ranged from 3 to 40 months. Notably, patients with oligodendrogliomas exhibited a significantly higher incidence of radiation necrosis (26%), underscoring a substantial risk association (<i>P</i> < 0.001). Conversely, the rates of radiation necrosis in patients with glioblastoma and astrocytoma (WHO grade II and III) were lower, at 2% and 0%, respectively, suggesting a lower risk association (<i>P</i> < 0.001 and <i>P</i> = 0.036, respectively). The majority (79%) of these patients were asymptomatic and exhibited a favorable clinical course, with most cases showing no progression of necrosis. During the follow-up period, tumor recurrence was verified in 2 patients.</p><p><strong>Conclusion: </strong>Radiation necrosis post-radiotherapy for primary brain tumors occurs infrequently but predominantly in patients with oligodendrogliomas, often following a benign course. The study underscores the importance of close monitoring for this condition, given the potential for sampling errors and the critical need for histopathological confirmation to guide appropriate management.</p>\",\"PeriodicalId\":19234,\"journal\":{\"name\":\"Neuro-oncology practice\",\"volume\":\"12 4\",\"pages\":\"670-677\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12349754/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/nop/npaf021\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/nop/npaf021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:放射性坏死是原发性脑肿瘤放疗后公认的并发症,给诊断和治疗带来挑战,并可能伪装成肿瘤复发。本研究旨在描述原发性脑肿瘤患者经组织学证实的放射性坏死的临床轨迹、管理策略和结果。方法:我们对2010年至2022年间在我院因疑似肿瘤复发而行手术治疗并接受辅助放疗的患者进行回顾性分析。对组织病理学证实的放射性坏死病例进行鉴定并分析其发病、临床症状、放射学特征、与放化疗的相关性、治疗方法和疾病进展。结果:276例疑似复发性脑肿瘤行手术治疗的患者中,14例(5%)经组织病理学诊断为放射性坏死。从放疗到诊断的潜伏期为3 ~ 40个月。值得注意的是,少突胶质细胞瘤患者的放射性坏死发生率明显更高(26%),强调了实质性的风险关联(P P P分别= 0.036)。这些患者中大多数(79%)无症状,表现出良好的临床病程,大多数病例没有坏死进展。随访期间,2例患者证实肿瘤复发。结论:原发性脑肿瘤放疗后放射性坏死的发生率较低,但主要发生在少突胶质细胞瘤患者中,通常是良性的。该研究强调了密切监测这种情况的重要性,因为可能存在抽样错误,并且迫切需要组织病理学确认来指导适当的管理。
Histopathologically confirmed radiation necrosis: Risk factors and clinical outcomes in patients with primary brain tumors.
Background: Radiation necrosis is a recognized complication following radiotherapy for primary brain tumors, presenting diagnostic and therapeutic challenges, and potentially masquerading as tumor recurrence. This study aims to delineate the clinical trajectory, management strategies, and outcomes of histologically confirmed radiation necrosis in patients treated for primary brain tumors.
Methods: We conducted a retrospective review of patients who underwent surgical intervention for suspected tumor recurrence at our institution between 2010 and 2022, following adjuvant radiotherapy. Cases with histopathologically confirmed radiation necrosis were identified and analyzed for onset, clinical symptoms, radiological features, correlation with radio- and chemotherapy, management approaches, and disease progression.
Results: Out of 276 patients operated for suspected recurrent brain tumors, 14 (5%) were histopathologically diagnosed with radiation necrosis. The latency period from radiotherapy to diagnosis ranged from 3 to 40 months. Notably, patients with oligodendrogliomas exhibited a significantly higher incidence of radiation necrosis (26%), underscoring a substantial risk association (P < 0.001). Conversely, the rates of radiation necrosis in patients with glioblastoma and astrocytoma (WHO grade II and III) were lower, at 2% and 0%, respectively, suggesting a lower risk association (P < 0.001 and P = 0.036, respectively). The majority (79%) of these patients were asymptomatic and exhibited a favorable clinical course, with most cases showing no progression of necrosis. During the follow-up period, tumor recurrence was verified in 2 patients.
Conclusion: Radiation necrosis post-radiotherapy for primary brain tumors occurs infrequently but predominantly in patients with oligodendrogliomas, often following a benign course. The study underscores the importance of close monitoring for this condition, given the potential for sampling errors and the critical need for histopathological confirmation to guide appropriate management.
期刊介绍:
Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving